Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to outsmart High-Risk leukemia

NCT ID NCT04659616

Recruiting now Disease control Sponsor: OHSU Knight Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This phase 1 trial is testing whether adding the targeted drug pemigatinib after standard chemotherapy can help people with newly diagnosed acute myeloid leukemia (AML). Pemigatinib blocks a protein called FGFR that may fuel leukemia growth. The study will enroll 32 adults with intermediate- or high-risk AML to find the best dose and see if it improves remission rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pemigatinib (a targeted drug that blocks FGFR, a protein that may help leukemia cells grow)
What this could lead to
If successful, this could lead to a new treatment option for people with high-risk AML, potentially improving remission rates and survival.
What could go wrong
This is an early phase 1 trial with only 32 participants, so it is too soon to know if pemigatinib is effective or safe. Side effects from the drug or chemotherapy are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • OHSU Knight Cancer Institute

    RECRUITING

    Portland, Oregon, 97239, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • UT Southwestern/Simmons Cancer Center-Dallas

    RECRUITING

    Dallas, Texas, 75390, United States

    Contact Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.